Photo from wikipedia
Everolimus, a selective inhibitor of mamalian target of rapamycin (mTORi), is considered to be an alternative immunosuppressive regimen in the liver transplantation (LT) setting. However, most of the transplant centers… Click to show full abstract
Everolimus, a selective inhibitor of mamalian target of rapamycin (mTORi), is considered to be an alternative immunosuppressive regimen in the liver transplantation (LT) setting. However, most of the transplant centers avoid its early use (i.e., during the first month) after LT mainly due to safety issues.
Keywords:
transplantation;
liver transplantation;
safety efficacy;
first month
Journal Title: Clinical Transplantation
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Transplantation
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!